Showing 4631-4640 of 8786 results for "".
- Accure Laser Gets CE Mark for Acne Treatmenthttps://practicaldermatology.com/news/accure-laser-gets-ce-mark-for-acne-treatment/2460386/Accure Acne, Inc. now has a European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands. Fo
- Survey: Social Media Isn’t All That Helpful for Growing Your Derm Practicehttps://practicaldermatology.com/news/survey-social-media-isnt-all-that-helpful-for-growing-your-derm-practice/2460384/Patients often do not take social media into consideration when looking for a dermatologist, according to a survey from researchers at the George Washington University. The survey appears in the Journal of Drugs in Derma
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- Positive Top-Line Results Seen for Otezla in Mild-To-Moderate Plaque Psoriasishttps://practicaldermatology.com/news/positive-top-line-results-seen-for-otezla-in-mild-to-moderate-plaque-psoriasis/2460382/Amgen’s Otezla produces significant improvements in measures of mild-to-moderate psoriasis, compared with placebo, according to a top-line results from the ADVANCE trial. ADVANCE is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy o
- Med Spas May Need a Post-COVID-19 Facelifthttps://practicaldermatology.com/news/medspas-may-need-a-post-covid-19-facelift/2460370/Everyone is feeling anxious about returning to public spaces including spas following the COVID-19 pandemic, according to the new ISPA Consumer Snapshot Initiative. “We know that COVID-19 has created a lot of uncertainty in many industries, including the spa industry,” says
- Urgent: CMS Extends MIPS Extreme and Uncontrollable Circumstances Exception Application Until 4/30/2020https://practicaldermatology.com/news/urgent-cms-extends-mips-extreme-and-uncontrollable-circumstances-exception-application/2460369/The Centers for Medicare & Medicaid Services (CMS) re-opened the 2019 MIPS Extreme and Uncontrollable Circumstances Exception Application to individuals, groups, and virtual groups, including those who have already submitted data, due to the 2019 Novel Coronavirus (COVID-19) pandemi
- AAD Survey: Most Americans Know Sun Protection Is Important, Still Don't Protect Themselveshttps://practicaldermatology.com/news/aad-survey-most-americans-know-sun-protection-is-important-but-still-dont-protect-themselves-1/2460367/Fully 76 percent of Americans agree that sun protection is an important healthy habit, yet only 41 percent report regularly protecting themselves outdoors — increasing their risk for skin cancer, according to a new survey from the American Academy of Dermatology. What’s more
- MD Survey: Telehealth Booming, Prescribing Habits Changing During Pandemichttps://practicaldermatology.com/news/md-survey-telehealth-booming-prescribing-habits-changing-during-pandemic/2460360/More than four-fifths of physicians saw fewer patients in late March, averaging 40 patients per week vs. 103 per week prior to March 2020, according to a new survey of 500 U.S physicians by AbelsonTaylor, a health and wellness marketing agency. What’s more, three-quarters of physi
- AAD Elects New Officers, Board Membershttps://practicaldermatology.com/news/aad-elects-new-officers-board-members/2460358/Mark D. Kaufmann, MD, FAAD, has been elected to lead the American Academy of Dermatology. He will be installed as president-elect in March 2021 and hold the office of president for one year beginning in March 2022. Dr. Kaufmann, who is a member of the Practical Dermatology®
- New Melanoma Test May Reduce Unnecessary Lymph Node Biopsieshttps://practicaldermatology.com/news/new-melanoma-test-may-reduce-unnecessary-lymph-node-biopsies-1/2460348/A new skin cancer test may reduce up to 42 percent of sentinel lymph node biopsies used in the diagnosis of patients with melanoma, researchers at SkylineDx and Mayo Clinic report. The study appears in